Back to top
more

STANDARD BIOTLS (LAB)

(Delayed Data from NSDQ)

$1.80 USD

1.80
3,576,839

+0.25 (16.13%)

Updated Aug 15, 2024 03:59 PM ET

After-Market: $1.80 0.00 (0.00%) 4:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 251)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for LAB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Standard BioTools Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 115 166 28 69 59
Receivables 20 17 18 25 19
Notes Receivable 0 0 0 0 0
Inventories 21 21 21 20 14
Other Current Assets 3 4 4 4 5
Total Current Assets 158 209 72 118 96
Net Property & Equipment 24 26 28 18 8
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 108 119 134 147 150
Deposits & Other Assets 2 3 4 5 5
Total Assets 323 390 275 325 265
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 55 0 0 0 0
Accounts Payable 9 8 11 9 7
Current Portion Long-Term Debt 5 2 7 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 21 15 14 29 13
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 15 14 15 13 12
Total Current Liabilities 109 43 50 54 33
Mortgages 0 0 0 0 0
Deferred Taxes/Income 15 19 28 38 20
Convertible Debt 1 55 54 54 54
Long-Term Debt 3 8 10 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1 1 1 1 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 160 161 181 186 111
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 311 311 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 861 847 831 816 778
Retained Earnings -1,001 -926 -736 -677 -624
Other Equity -2 -2 -1 0 -1
Treasury Stock 6 1 0 0 0
Total Shareholder's Equity 163 230 95 139 154
Total Liabilities & Shareholder's Equity 323 390 275 325 265
Total Common Equity -148 -81 95 139 154
Shares Outstanding 80.20 79.30 76.40 74.10 69.50
Book Value Per Share -1.85 -1.03 1.24 1.88 2.21

Fiscal Year End for Standard BioTools Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 395 462 115 129 142
Receivables 32 36 20 17 15
Notes Receivable 0 0 0 0 0
Inventories 43 40 21 22 22
Other Current Assets 10 9 3 3 4
Total Current Assets 480 548 158 171 183
Net Property & Equipment 43 45 24 25 25
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 20 18 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 130 131 108 110 113
Deposits & Other Assets 4 4 2 2 3
Total Assets 709 778 323 339 356
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 55 55 55 0 0
Accounts Payable 13 13 9 7 6
Current Portion Long-Term Debt 0 0 5 5 5
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 32 30 21 21 17
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 19 17 15 15 15
Total Current Liabilities 124 122 109 52 47
Mortgages 0 0 0 0 0
Deferred Taxes/Income 43 45 15 16 17
Convertible Debt 0 0 1 55 55
Long-Term Debt 0 0 3 5 6
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2 1 1 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 198 200 160 160 158
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 311 311 311
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,682 1,675 861 857 853
Retained Earnings -1,125 -1,079 -1,001 -981 -960
Other Equity -2 -2 -2 -2 -2
Treasury Stock 46 17 6 6 5
Total Shareholder's Equity 510 577 163 180 198
Total Liabilities & Shareholder's Equity 709 778 323 339 356
Total Common Equity 510 577 -148 -132 -113
Shares Outstanding 370.40 380.40 80.20 78.90 78.30
Book Value Per Share 1.38 1.52 -1.85 -1.67 -1.45